NASDAQ:GTHX - G1 Therapeutics Stock Price, Forecast & News

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

G1 Therapeutics Inc (NASDAQ:GTHX) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.01. View G1 Therapeutics' Earnings History.

G1 Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for G1 Therapeutics.

7 analysts have issued 1 year target prices for G1 Therapeutics' shares. Their forecasts range from $45.00 to $82.00. On average, they anticipate G1 Therapeutics' stock price to reach $67.17 in the next year. This suggests a possible upside of 176.5% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.

Press coverage about GTHX stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. G1 Therapeutics earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for G1 Therapeutics.

G1 Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totalling 4,080,000 shares, a decline of 13.7% from the December 15th total of 4,730,000 shares. Based on an average trading volume of 333,300 shares, the days-to-cover ratio is presently 12.2 days. Currently, 13.5% of the shares of the stock are sold short. View G1 Therapeutics' Current Options Chain.

Some companies that are related to G1 Therapeutics include Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Deciphera Pharmaceuticals (DCPH), Myokardia (MYOK), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), Agios Pharmaceuticals (AGIO), Zai Lab (ZLAB), Axsome Therapeutics (AXSM), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Alkermes (ALKS) and Genmab A/S (GMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Rite Aid (RAD), OASMIA PHARMACE/ADR (OASM), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Exelixis (EXEL), Kala Pharmaceuticals (KALA), Viking Therapeutics (VKTX), Bellicum Pharmaceuticals (BLCM), Corbus Pharmaceuticals (CRBP) and Eyepoint Pharmaceuticals (EYPT).

(GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

G1 Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.70%) and Alpine Global Management LLC (0.04%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.

GTHX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for G1 Therapeutics.

GTHX stock was purchased by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson and John Demaree. View Insider Buying and Selling for G1 Therapeutics.

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GTHX stock can currently be purchased for approximately $24.29.

G1 Therapeutics has a market capitalization of $912.82 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics.

The official website for G1 Therapeutics is http://www.g1therapeutics.com/.

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]